Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease
Rhea-AI Summary
Profound Medical (NASDAQ:PROF) received INOVAIT’s 2025–2026 Mount Logan Award for the TULSA Procedure™ and its commercial milestones. Key highlights include treating the 4,000th TULSA patient, securing new U.S. Medicare reimbursement codes, regaining exclusive Canadian distribution rights, and expanding global access via partnerships and a North America direct sales team.
The TULSA-PRO® system uses robotically controlled directional ultrasound with real-time MRI thermography to heat prostate tissue precisely, aiming to minimize blood loss, hospital stays, and common surgery or radiation side effects.
Positive
- 4,000 TULSA Procedures completed globally
- Secured new U.S. Medicare reimbursement codes
- Regained exclusive Canadian distribution rights
- Deploying a direct sales team in North America
Negative
- Only one TULSA-PRO system currently installed in Canada
- Sunnybrook performed >100 procedures without provincial coverage
News Market Reaction – PROF
On the day this news was published, PROF declined 3.26%, reflecting a moderate negative market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $8M from the company's valuation, bringing the market cap to $246M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PROF gained 1.26% while key peers were mixed: OWLT -9.04%, RCEL -4.48%, LNSR -0.24%, SERA -3%, and RPID +3.19%, pointing to a stock-specific response to the award and TULSA recognition.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Sonalleve usage milestone | Positive | -7.3% | PRO FAMILIA hospital reached 500th Sonalleve procedure and highlighted global usage. |
| Jan 27 | Investor conferences | Neutral | -2.3% | Company announced participation in two February 2026 life-science investor events. |
| Jan 15 | TULSA-PRO regional launch | Positive | +9.4% | Mount Sinai became first in New York Metro to offer incision-free TULSA-PRO treatment. |
| Jan 12 | Installed base update | Positive | +2.5% | Year-end TULSA-PRO installed base reached 78 systems, above the 2025 goal. |
| Jan 06 | First commercial case | Positive | -0.5% | Johns Hopkins treated its first commercial TULSA-PRO prostate cancer patient. |
Adoption and commercialization milestones for TULSA-PRO and Sonalleve have produced mixed reactions, with some positive operational updates followed by share price declines and others seeing gains.
Over the past months, Profound Medical has highlighted commercialization and adoption milestones. On Jan 6 and Jan 15, first commercial and regional TULSA-PRO cases at Johns Hopkins and Mount Sinai underscored traction in leading U.S. centers, with mixed price reactions. A 78-system TULSA-PRO installed base and 97-system pipeline update on Jan 12 also tied to growth expectations. The current INOVAIT Mount Logan Award and 4,000th TULSA patient build on this momentum narrative around prostate care innovation.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Nov 13, 2025 allows Profound Medical to offer up to $150,000,000 of securities, including common shares, warrants, debt, subscription receipts, and units for working capital, capital expenditures, and general corporate purposes. As of the latest data, the shelf is not yet effective and has 0 recorded usage.
Market Pulse Summary
This announcement underscores Profound’s progress in MRI-guided prostate care, with INOVAIT’s Mount Logan Award recognizing achievements including the 4,000th TULSA patient and more than 100 procedures at Sunnybrook. The company recently regained Canadian distribution rights and is building a direct North American sales team. Investors may watch for further system installs, procedure growth, and any use of the existing $150,000,000 shelf registration as the commercialization strategy advances.
Key Terms
interventional mri medical
image-guided therapy medical
benign prostatic hyperplasia medical
robotically controlled directional ultrasound medical
mri thermography medical
AI-generated analysis. Not financial advice.
TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is pleased to announce that it has received the 2025/2026 Mount Logan Award from INOVAIT, the Canadian national network for commercializing breakthroughs in image-guided therapy (IGT) and artificial intelligence (“AI”).
“The Mount Logan Award recognizes an INOVAIT industry member who has consistently exceeded project milestone expectations, reached new heights as a Canadian company, and stood out internationally,” said Raphael Ronen, co-executive director of INOVAIT. “Profound Medical has achieved significant milestones and international acclaim over the last year, including treating their 4,000th TULSA Procedure patient, securing new U.S. reimbursement codes from Medicare, and establishing strategic partnerships to expand patient access globally, and is, therefore, worthy of celebrating with the Mount Logan Award.”
The iMRI TULSA Procedure™, performed using the TULSA-PRO® system, represents a major advancement in prostate care, and is used by physicians to treat men with prostate cancer and/or benign prostatic hyperplasia (“BPH”, also known as an enlarged prostate). Robotically controlled directional ultrasound is delivered from inside the urethra to precisely and gently heat prostate tissue to ‘kill temperature’ (55-57°C), while protecting surrounding nerves and anatomy. Real-time MRI thermography enables continuous visualization and autonomous temperature adjustment throughout the procedure. This level of precision allows physicians to tailor therapy to each patient, resulting in no procedural blood loss, no overnight hospital stay, and a quicker return to everyday life, while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.
“We are incredibly honored to receive this award as we work to drive widespread global commercialization of a home-grown Canadian medical innovation,” said Arun Menawat, Profound Medical’s CEO and Chairman. “While currently only one TULSA-PRO system install resides in Canada, we hope to change that moving forward as we just recently regained exclusive distribution rights in the country from a previous partner. In the meantime, the importance of that single current commercial placement in Canada can’t be overstated. Toronto’s renowned Sunnybrook Health Sciences Centre, the original innovator of the TULSA-PRO technology, has already performed more than 100 TULSA Procedures despite it not being covered by a provincial health insurance plan. Moving forward, as user interest in Profound’s technologies continues to build, we are deploying our own direct sales team in North America, while partnering with select strategic distribution partners to support the business potential and the customer base in other parts of the world."
“We are deeply grateful to INOVAIT for supporting a vision where AI‑enabled, image‑guided therapies like TULSA-PRO are not only developed in Canada, but lead the world,” added Mathieu Burtnyk, Profound Medical’s President. “That support gives companies like ours the momentum to turn bold ideas into real clinical impact.”
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets innovative iMRI procedures.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. The TULSA Procedure is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with the TULSA Procedure. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
Forward-Looking Statements
This press release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer, BPH, uterine fibroids, palliative pain treatment and osteoid osteoma; and the success of Profound’s commercialization strategy and activities for TULSA-PRO®. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound's Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.ca and www.sec.gov. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
Susan Thomas
Public Relations
sthomas@profoundmedical.com
T: 619.540.9195
FAQ
What did Profound Medical (PROF) announce on February 12, 2026 about the TULSA Procedure?
How many TULSA Procedures has Profound Medical (PROF) reported as of Feb 12, 2026?
What is the clinical benefit of the TULSA-PRO system highlighted by Profound Medical (PROF)?
What commercial progress did Profound Medical (PROF) cite alongside the Mount Logan Award?
Is TULSA covered by provincial health insurance in Canada according to Profound Medical (PROF)?
